Arcturus Therapeutics (NASDAQ: ARCT) reported Q1 EPS of $1.87, $1.81 better than the analyst estimate of $0.06. Revenue for the quarter came in at $80.3 million versus the consensus estimate of $37.94 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.